<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Calistoga Drug Shrinks Tumors in Lab Studies</title>
	<atom:link href="http://www.xconomy.com/seattle/2008/12/09/calistoga-drug-shrinks-tumors-in-lab-studies/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/seattle/2008/12/09/calistoga-drug-shrinks-tumors-in-lab-studies/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 11 Feb 2012 01:49:51 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
	<item>
		<title>By: Cell pathway on overdrive prevents normal cancer response to dietary restriction &#124; Pharma Strategy Blog</title>
		<link>http://www.xconomy.com/seattle/2008/12/09/calistoga-drug-shrinks-tumors-in-lab-studies/comment-page-1/#comment-240537</link>
		<dc:creator>Cell pathway on overdrive prevents normal cancer response to dietary restriction &#124; Pharma Strategy Blog</dc:creator>
		<pubDate>Tue, 26 Oct 2010 21:24:08 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=6762#comment-240537</guid>
		<description>[...] Calistoga Drug Shrinks Tumors in Lab Studies (xconomy.com)         This entry was posted in Cancer, Mechanism of Action, New products, Pipeline, Science, Targeted Therapies, Technology and tagged competitive intelligence, forecasting portfolio analysis, M&amp;A due diligence, oncology cancer, pharmaceutical biotechnology marketing strategy. Bookmark the permalink.    &#8592; MicroRNA-based Diagnostic Identifies Squamous Lung Cancer With 96% Sensitivity Herceptin proven to benefit women with HER2 positive early breast cancer &#8594;        blog comments powered by Disqus  /*  */   /*  */   /*  */ [...]</description>
		<content:encoded><![CDATA[<p>[...] Calistoga Drug Shrinks Tumors in Lab Studies (xconomy.com)         This entry was posted in Cancer, Mechanism of Action, New products, Pipeline, Science, Targeted Therapies, Technology and tagged competitive intelligence, forecasting portfolio analysis, M&amp;A due diligence, oncology cancer, pharmaceutical biotechnology marketing strategy. Bookmark the permalink.    ← MicroRNA-based Diagnostic Identifies Squamous Lung Cancer With 96% Sensitivity Herceptin proven to benefit women with HER2 positive early breast cancer →        blog comments powered by Disqus  /*  */   /*  */   /*  */ [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Calistoga Pharmaceuticals &#171; Ask Lazlo</title>
		<link>http://www.xconomy.com/seattle/2008/12/09/calistoga-drug-shrinks-tumors-in-lab-studies/comment-page-1/#comment-43070</link>
		<dc:creator>Calistoga Pharmaceuticals &#171; Ask Lazlo</dc:creator>
		<pubDate>Tue, 16 Dec 2008 20:04:15 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=6762#comment-43070</guid>
		<description>[...] News: Lead drug CAL-101 is said to kill tumor cells (Dec. 9, 2008) [...]</description>
		<content:encoded><![CDATA[<p>[...] News: Lead drug CAL-101 is said to kill tumor cells (Dec. 9, 2008) [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

